ArticleJournal of translational medicine2026

Targeting C5AR1 disrupts complement-driven G0-phase maintenance and overcomes metabolic drug resistance in glioma.

Yu Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.